RESPIROLOGY is a prestigious academic journal that focuses on the field of Pulmonary and Respiratory Medicine, publishing high-quality research and comprehensive reviews that contribute significantly to the understanding and management of respiratory health. As a distinguished publication of WILEY, it has established a strong presence in the academic world with an impressive impact factor and ranked in the Q1 category, recognized for its influence and innovation in the field. RESPIROLOGY is committed to disseminating cutting-edge research from 1996 through 2024, appearing regularly in SCOPUS with a rank of #14 out of 155, placing it in the rarefied 91st percentile among its peers. The journal invites contributions from researchers, professionals, and students, fostering a collaborative space for advancing knowledge in pulmonary medicine. Although it does not offer open access, its readership spans globally, indicating the high regard in which it is held within the scientific community.

CHEST is a premier journal published by Elsevier, focusing on the vital fields of cardiology, critical care, and pulmonary medicine. Established in 1970, this esteemed journal has continually provided authoritative research, reviews, and clinical studies, catering to a global audience of healthcare professionals, researchers, and students. With an impressive impact factor, CHEST ranks in the top quartile (Q1) across its core categories according to the latest Scopus metrics, securing its position as a leading resource within cardiology (Rank #16), pulmonary (Rank #9), and critical care (Rank #8). Published quarterly, it offers a wealth of knowledge essential for advancing understanding and improving patient outcomes in these critical areas of healthcare. Researchers and practitioners are encouraged to submit their work, contributing to the ongoing discourse that shapes innovative practices and policies in respiratory and cardiovascular health.

The EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.

The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.

The Lancet Respiratory Medicine, published by Elsevier in the United Kingdom, is a premier journal dedicated to the field of pulmonary and respiratory medicine. With its impressive impact factor and a prestigious ranking of #1 out of 155 in its category as of 2023, it holds a remarkable position in advancing research and clinical practices in respiratory health. The journal invites original research, reviews, and clinical studies that aim to propel the understanding of respiratory diseases, fostering innovations in treatment and management strategies. Operating under a Q1 category in Scopus rankings, it is an essential platform for researchers, healthcare professionals, and students who are committed to enhancing patient care and advancing knowledge in this crucial area of medicine. The Lancet Respiratory Medicine remains a vital resource for the latest findings and discussions shaping the future of respiratory health.

Pulmonary Medicine, published by HINDAWI LTD, stands as a prestigious open-access journal since 2010, dedicated to advancing the field of pulmonary and respiratory medicine. Located in Egypt, this journal is indexed with an ISSN of 2090-1836 and an E-ISSN of 2090-1844, and it has attained a commendable Q2 ranking in both the miscellaneous medicine and pulmonary health categories, indicative of its significant impact and quality. With an impressive Scopus ranking of #15 out of 155 in the pulmonary and respiratory medicine category, the journal is positioned in the 90th percentile, highlighting its relevance and contribution to ongoing research. The journal aims to publish high-quality original research, reviews, and clinical studies that address pressing issues in pulmonary health, making it a vital resource for researchers, clinicians, and students seeking to enhance their understanding and practice in respiratory medicine. By embracing an open-access model, Pulmonary Medicine provides a platform for disseminating knowledge, fostering collaboration, and driving innovation within the global scientific community.

Annals of Thoracic Medicine is a prominent open-access journal, published by Wolters Kluwer Medknow Publications, focusing on the critical fields of cardiology, pulmonary and respiratory medicine, and surgery. With an ISSN of 1817-1737 and an E-ISSN of 1998-3557, this journal aims to disseminate cutting-edge research, clinical findings, and innovative practices that can significantly impact the health outcomes of patients dealing with thoracic diseases. Since its inception in 2006, it has established itself as a reputable source of knowledge, achieving Q2 quartile rankings in 2023 across its main categories. Currently ranked #126 in Medicine & Surgery and exhibiting a growing SCOPUS percentile, the journal plays an essential role in advancing the understanding and treatment of thoracic conditions. Open access options ensure that research is readily available to a global audience, facilitating collaboration and knowledge sharing among researchers, healthcare professionals, and students in the field.

Jornal Brasileiro de Pneumologia is a pivotal open-access journal in the field of Pulmonary and Respiratory Medicine, published by SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA. Established in 2004, this esteemed publication has become a significant platform for researchers, health professionals, and students in Brazil and beyond, facilitating the exchange of innovative ideas and vital research findings. The journal is indexed in Scopus and is recognized in the 2023 category quartiles as Q3, ranking 86 out of 155 in its field with a corresponding 44th percentile. This reflects its growing influence and commitment to advancing knowledge concerning respiratory health. With a mission to disseminate high-quality research, the journal aims to foster advancements in clinical practice and improve outcomes in pulmonary diseases, making it an essential resource for those dedicated to enhancing the quality of care in respiratory medicine. For those seeking comprehensive access to critical studies and reviews in this domain, the Jornal Brasileiro de Pneumologia remains an invaluable asset.

LUNG is a prestigious academic journal that has been a cornerstone in the field of Pulmonary and Respiratory Medicine since its inception in 1959. Published by SPRINGER, the journal holds an impressive Q1 ranking in its category for 2023, reflecting its commitment to disseminating high-quality research and advancing clinical practices in respiratory health. With a Scopus rank of 24 out of 155 in its field, representing the top 16% of journals, LUNG continues to serve as a vital platform for researchers, clinicians, and students who are dedicated to addressing the complexities of lung diseases. Although currently not an open-access journal, LUNG offers valuable insights and significant contributions to the understanding of respiratory conditions, ensuring that its readership stays at the forefront of medical advancements. Researchers and professionals are encouraged to submit their work and engage with a thriving academic community that is passionate about improving patient outcomes in pulmonary health.

REVUE DES MALADIES RESPIRATOIRES is a distinguished journal published by MASSON EDITEUR, focusing on the vital field of pulmonary and respiratory medicine. Established in 1984, this journal has become a prominent platform for sharing innovative research and clinical findings, reflecting an impressive array of studies that contribute to our understanding of respiratory diseases. With its ISSN 0761-8425 and E-ISSN 1776-2588, it facilitates access to scholarly work within the medical community, although it currently operates under a subscription model rather than Open Access. As indicated by its quartile ranking of Q4 in 2023 within its category and a Scopus rank of #128/155, REVUE DES MALADIES RESPIRATOIRES serves as an essential resource for researchers, professionals, and students aiming to stay informed about advancements in respiratory health. This journal plays a crucial role in fostering discussions that drive innovation and best practices in the treatment and understanding of respiratory conditions.